Latest France News

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

Steadfast Group has reported a robust 17.2% increase in underlying net profit after tax for FY25, alongside a 14% rise in its fully franked final dividend, underpinned by both organic growth and strategic acquisitions.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.

Ramsay Health Care posted solid revenue growth driven by its Australian and UK hospital businesses, despite a significant impairment charge impacting net profit. The group advances a multi-year transformation focusing on operational efficiency and capital discipline.

Atlas Arteria’s half-year report for June 2025 reveals stable traffic and revenue growth across its French, German, and US toll road assets, underpinned by disciplined financial management and strategic capital investments.

Atlas Arteria reported a 32.9% drop in statutory net profit for H1 2025 due to a new French tax, yet achieved solid toll revenue and EBITDA growth, maintaining its 2025 distribution guidance.

Atlas Arteria reported a statutory net profit of $73.3 million for H1 2025, impacted by a new tax, while toll revenues rose 8.1%. The company reaffirmed its 2025 distribution guidance of 40 cents per security, supported by strong free cash flow growth.

Atlas Arteria reported an 11.4% rise in revenue for the half year ended June 2025, driven by toll growth across its global portfolio. However, net profit fell 32.9% due to a one-off French tax and ongoing challenges in the US.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Lovisa Holdings has reported a robust FY25 with revenue climbing 14.2% and over 160 new stores opened worldwide, signaling strong momentum in the fashion jewellery sector.

Domino’s Pizza Enterprises reported a modest dip in FY25 sales and earnings amid a strategic reset focused on cost efficiency and franchisee support. The company aims to rebuild momentum through targeted reinvestment and operational simplification.